Related Experiment Videos
[Detection of hepatitis B surface antigen using passive hemagglutination]
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii
|March 1, 1986
Summary
A new passive hemagglutination test, Sero-Test CCB, detects hepatitis B surface antigen (HBsAg). It shows high agreement with another test and is more sensitive than electrophoresis, though less sensitive than radioimmunoassay.
Area of Science:
- Clinical Virology
- Immunodiagnostics
- Public Health
Background:
- Hepatitis B virus (HBV) infection remains a significant global health concern.
- Accurate and sensitive detection of hepatitis B surface antigen (HBsAg) is crucial for diagnosis, screening, and prevention strategies.
- Existing diagnostic methods vary in sensitivity and applicability.
Purpose of the Study:
- To evaluate the newly developed passive hemagglutination test, Sero-Test CCB, for HBsAg detection.
- To compare the sensitivity of Sero-Test CCB against another passive hemagglutination test (Hepanostikon) and radioimmunoassay (RIA).
- To assess the utility of Sero-Test CCB in clinical settings, including donor blood screening and high-risk group surveillance.
Main Methods:
- A comparative study involving 100 coded sera from hepatitis patients and carriers.
- Determination of HBsAg using Sero-Test CCB, Hepanostikon, and an experimental RIA kit.
- Statistical analysis to compare test results and assess sensitivity.
Main Results:
- Sero-Test CCB demonstrated coinciding results with the Hepanostikon test (correlation coefficient r = 0.90).
- The sensitivity of Sero-Test CCB was 30-150 times greater than electrophoretic techniques.
- Sero-Test CCB exhibited 8 times lower sensitivity compared to radioimmunoassay.
Conclusions:
- Sero-Test CCB is a viable passive hemagglutination assay for HBsAg detection with good concordance with existing methods.
- The test offers significantly improved sensitivity over electrophoretic methods for HBsAg screening.
- Sero-Test CCB is suitable for routine examination of donor blood and surveillance in high-risk populations, such as those in hemodialysis and transplantation centers.